IR Overview

Thank you for your interest in Adaptimmune. We are a leader in the TCR T-cell therapy space focused on novel cancer immunotherapy products. We utilize the body’s own machinery – the T-cell – to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). The result of our efforts are SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cell therapies that can recognize cancer proteins, and as a result detect and fight cancer within patients.

SPEAR T-cell therapies targeting MAGE-A10, MAGE-A4, AFP, and NY-ESO are moving through clinical studies in multiple cancer types.

$8.280.00 (0.00%)
ADAP (American Depositary Shares)
ExchangeNASDAQ GS (US Dollar)
Today's Open$8.30
Previous Close$8.28
Data as of 09/20/17 4:00 p.m.
Refresh quote
Data provided by Nasdaq. Minimum 15 minutes delayed.
Recent NewsMore >>
09/07/17GSK Exercises Option over SPEAR T-cell Therapy Program Targeting NY-ESO
PHILADELPHIA and OXFORD, United Kingdom, Sept. 07, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that GlaxoSmithKline plc (LSE:GSK) (NYSE:GSK) has exercised its option under a collaboration and license agreement signed in 2014 to exclusively license the right to research, develop, and commercialize Adaptimmune’s NY-ESO SPEAR T-cell therapy program. Further details will be provided in a conference call scheduled ... 
Printer Friendly Version
08/30/17Adaptimmune to Present at Upcoming CAR-TCR Summit; CEO James Noble to be a Keynote Speaker
PHILADELPHIA and OXFORD, U.K., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced its participation in the CAR-TCR Summit in Boston on Tuesday, September 5, and Wednesday, September 6 at the Seaport Hotel & World Trade Center; One Seaport Lane, Boston, MA 02210. The CAR-TCR summit highlights leaders in the CAR-T and TCR space to create a platform for cell immunotherapy expert... 
Printer Friendly Version
08/03/17Adaptimmune Reports Second Quarter 2017 Financial Results
– A registered direct offering in April combined with a public offering in March raised net proceeds of $103.2 million; operations funded through to late 2019 –        – Enrolling 9 clinical studies with NY-ESO as well as our wholly-owned assets (MAGE-A4, MAGE-A10, and AFP) across 12 different tumor indications – – On track for initial data from our wholly-owned assets in 2017 and 2018 –             – NY-ESO data presented at the Annual American Society of Clinical Oncology Meeting (ASCO) c... 
Printer Friendly Version
07/31/17Adaptimmune to Report Second Quarter 2017 Financial Results on August 3, 2017
PHILADELPHIA and OXFORD, United Kingdom, July 31, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer will announce financial results for the quarter ended June 30, 2017 before the open of the U.S. markets on Thursday, August 3, 2017. The Company will not be hosting a live teleconference this quarter. The press release will be available in the investor section of Adaptimmune’s corporate website at About Adapti... 
Printer Friendly Version
Upcoming EventsMore >>
09/25/17 9:15 a.m. ET
Adaptimmune at Cell and Gene Therapy CEO Conference
LocationFour Seasons Hotel
Boston, MA
09/28/17 10:30 a.m. ET
Adaptimmune at Leerink Partners Roundtable Series: Rare Disease and Immuno-oncology
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Adaptimmune posts new information to the site. Just enter your e-mail address and click Submit.